This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Camarillo-based ImmPact Bio made multiple headlines with one announcement on Jan. 20: the a new CEO, a new board chair, and the closing of a $111 million Series B funding round. ImmPact, a biotechnology company developing cancer treatments based on chimeric antigen receptor (CAR) T-cell therapies, named Sumant Ramachandra as its new president and CEO. Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.